N-(1,2,3,4-tetrahydro-6-quinolyl)trifluoroacetamide | 157589-45-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-(1,2,3,4-tetrahydro-6-quinolyl)trifluoroacetamide
• 英文别名: 6-(2,2,2-trifluoroacetylamino)-1,2,3,4-tetrahydroquinoline；6-trifluoroacetylamino-1,2,3,4-tetrahydro-quinoline；2,2,2-trifluoro-N-(1,2,3,4-tetrahydroquinolin-6-yl)acetamide
• CAS: 157589-45-2
• 化学式: C₁₁H₁₁F₃N₂O
• 分子量: 244.216
• InChiKey: GAPWUKPSRLTVQM-UHFFFAOYSA-N

物化性质

• 沸点：
  365.1±42.0 °C(Predicted)
• 密度：
  1.343±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-(1,2,3,4-tetrahydro-6-quinolyl)trifluoroacetamide 在 吡啶 、 sodium hydroxide 、 sodium hydride 、 potassium carbonate 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 、 1,2-二氯乙烷 为溶剂， 反应 117.33h， 生成 1-methyl-5,6,7,8-tetrahydro-1H-pyrrolo<2,3-g>quinoline
  参考文献：
  名称：

  5-Methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2,3-f]indole: A Novel 5-HT2C/5-HT2B Receptor Antagonist with Improved Affinity, Selectivity, and Oral Activity

  摘要：

  The preparation of a series of conformationally restricted analogues of indolylurea 1, namely tetrahydropyrroloindoles and tetrahydropyrroloquinolines, is described. The binding affinities of these compounds at 5-HT2A, 5-HT2B, and 5-HT2C receptors were determined. Of these compounds, the 1,2,3,5-tetrahydropyrrolo[2,3-f]indole derivative, compound 11, was found to have high affinity for the 5-HT2C (pK(I) 8.0) and 5-HT2B receptors (pA(2) 8.5), with excellent selectivity over the 5-HT2A and various other receptors (pK(I) <6). 11 is also considerably more active than 1 in both an in vitro functional model, 5-HT-stimulated phosphoinositol hydrolysis (pK(B) 8.8), and an in vivo functional model, mCPP-induced hypolocomotion (ID50 5.5 mg/kg po). 11 should therefore be of significant utility as a pharmacological tool to delineate the functional significance of blockade of 5-HT2B and 5-HT2C receptors.

  DOI：

  10.1021/jm00014a004
• 作为产物：
  描述：

  6-氨基喹啉 在 sodium tetrahydroborate 、 三乙胺 、 nickel dichloride 作用下， 以 甲醇 、 氯仿 为溶剂， 反应 8.0h， 生成 N-(1,2,3,4-tetrahydro-6-quinolyl)trifluoroacetamide
  参考文献：
  名称：

  5-Methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2,3-f]indole: A Novel 5-HT2C/5-HT2B Receptor Antagonist with Improved Affinity, Selectivity, and Oral Activity

  摘要：

  The preparation of a series of conformationally restricted analogues of indolylurea 1, namely tetrahydropyrroloindoles and tetrahydropyrroloquinolines, is described. The binding affinities of these compounds at 5-HT2A, 5-HT2B, and 5-HT2C receptors were determined. Of these compounds, the 1,2,3,5-tetrahydropyrrolo[2,3-f]indole derivative, compound 11, was found to have high affinity for the 5-HT2C (pK(I) 8.0) and 5-HT2B receptors (pA(2) 8.5), with excellent selectivity over the 5-HT2A and various other receptors (pK(I) <6). 11 is also considerably more active than 1 in both an in vitro functional model, 5-HT-stimulated phosphoinositol hydrolysis (pK(B) 8.8), and an in vivo functional model, mCPP-induced hypolocomotion (ID50 5.5 mg/kg po). 11 should therefore be of significant utility as a pharmacological tool to delineate the functional significance of blockade of 5-HT2B and 5-HT2C receptors.

  DOI：

  10.1021/jm00014a004

文献信息

• Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
  申请人：——

  公开号：US20020103203A1

  公开（公告）日：2002-08-01

  Amide compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction in order to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

  描述了调节和/或抑制特定蛋白激酶活性的酰胺化合物。这些化合物和含有它们的药物组合物能够介导酪氨酸激酶信号传导，以调节和/或抑制不需要的细胞增殖。该发明还涉及含有这些化合物的药物组合物的治疗或预防用途，以及通过给予这些化合物的有效量来治疗癌症以及与不需要的血管生成和/或细胞增殖相关的其他疾病状态，如糖尿病视网膜病变、新生血管性青光眼、类风湿性关节炎和牛皮癣的方法。
• Antithrombotic phenylalkyl derivatives
  申请人：Boehringer Ingelheim Pharm KG

  公开号：US06300342B1

  公开（公告）日：2001-10-09

  Antithrombotic phenylalkyl derivatives of the formula Exemplary compounds are: (a) 1-[3-(4-amidino-phenyl)propionyl]-6-(4-fluoro-phenylsulphonamido)-1,2,3,4-tetrahydro-quinoline, (b) 1-[3-(4-amidino-phenyl)propionyl]-6-butylsulphonamido-1,2,3,4-tetrahydro-quinoline, (c) 1-[3-(4-amidino-phenyl)propionyl]-5-phenylsulphonamido-1,2,3,4-tetrahydro-quinoline, (d) 1-[3-(4-amidino-phenyl)propionyl]-3-methyl-6-phenylsulphonamido-1,2,3,4-tetrahydro-quinoline, and, (e) 1-[3-(4-amidino-phenyl)propionyl]-6-(5-chloro-thien-2-ylsulphonamido)-1,2,3,4-tetrahydro-quinoline.

  抗血栓酚烯基衍生物的化学式示例化合物为：(a) 1-[3-(4-氨基甲酰基苯基)丙酰基]-6-(4-氟苯磺胺基)-1,2,3,4-四氢喹啉，(b) 1-[3-(4-氨基甲酰基苯基)丙酰基]-6-丁基磺胺基-1,2,3,4-四氢喹啉，(c) 1-[3-(4-氨基甲酰基苯基)丙酰基]-5-苯基磺胺基-1,2,3,4-四氢喹啉，(d) 1-[3-(4-氨基甲酰基苯基)丙酰基]-3-甲基-6-苯基磺胺基-1,2,3,4-四氢喹啉，以及，(e) 1-[3-(4-氨基甲酰基苯基)丙酰基]-6-(5-氯噻吩-2-基磺胺基)-1,2,3,4-四氢喹啉。
• [DE] PHENYLALKYLDERIVATE MIT THROMBINHEMMENDER WIRKUNG<br/>[EN] PHENYLALKYL DERIVATIVES WITH THROMBIN-INHIBITING EFFECT<br/>[FR] DERIVES PHENYLALKYLES A EFFET INHIBITEUR DE THROMBINE
  申请人：BOEHRINGER INGELHEIM PHARMA KG

  公开号：WO1999000371A1

  公开（公告）日：1999-01-07

  (DE) Die vorliegende Erfindung betrifft Phenylalkylderivate der allgemeinen Formel (I), in der A, B, W, Y und Ra bis Rd wie im Anspruch 1 definiert sind, deren Tautomere, deren Stereoisomere, deren Gemische und deren Salze, welche wertvolle Eigenschaften aufweisen. So stellen die Verbindungen der allgemeinen Formel (I), in denen Rb ein Wasserstoffatom, eine Nitro- oder Cyanogruppe darstellt, wertvolle Zwischenprodukte zur Herstellung der übrigen Verbindungen der allgemeinen Formel (I) dar, und die Verbindungen der allgemeinen Formel (I), in denen Rb eine der im Anspruch 1 erwähnten gegebenenfalls substituierten Aminomethyl- oder Amidinogruppen darstellt, sowie deren Tautomere und deren Stereoisomere weisen wertvolle pharmakologische Eigenschaften auf, insbesondere eine Trombin-hemmende und die Thrombinzeit verlängernde Wirkung.(EN) The invention relates to phenylalkyl derivatives of general formula (I) in which A, B, W, Y and Ra to Rd are as defined in claim 1, their tautomers, their stereoisomers, their mixtures and their salts with valuable properties. The compounds of general formula (I), in which Rb is a hydrogen atom, a nitro group or a cyano group, are valuable intermediates for producing the other compounds of general formula (I). Furthermore, the compounds having general formula (I), in which Rb is one of the optionally substituted aminomethyl or amidino groups mentioned in claim 1, as well as their tautomers and stereoisomers, have valuable pharmacological properties, in particular as thrombin inhibitors and in extending the thrombin time.(FR) L'invention concerne des dérivés phénylalkylés de formule générale (I) dans laquelle A, B, W, Y et Ra à Rd sont tels que définis dans la revendication 1, leurs tautomères, leurs stéréoisomères, leurs mélanges et leurs sels présentant des propriétés de valeur. C'est ainsi que les composés de formule générale (I), pour lesquels Rb est un atome d'hydrogène, un groupe nitro ou un groupe cyano, constituent des produits intermédiaires de valeur pour la fabrication des autres composés de formule générale (I), et les composés de formule générale (I), pour lesquels Rb désigne l'un des groupes aminométhyle ou amidino éventuellement substitués, mentionnés dans la revendication 1, ainsi que leurs tautomères et leurs stéréoisomères présentent des propriétés pharmacologiques de valeur, en particulier un effet inhibiteur de thrombine et un effet prolongeant le temps de thrombine.

  本发明涉及一般式为(I)的苯甲基衍生物，其中A、B、W、Y和Ra至Rd的定义如附请之。它们的自体和它们的构型异构体，它们的混合物及其盐，具有有价值的性质。一般式为(I)的化合物，其中Rb为一个氢原子、一个硝基或者一个ictionary(cyanide)基团，是用于生产一般式为(I)化合物而非常重要的中间体。此外，一般式为(I)式中Rb为附请中所说明的任一可提供的氨基甲基或酰胺基的衍生物的化合物及其自体和构型异构体，是很有价值的医药性质的，特别地，这种化合物是抗血小板聚集剂且具有延缓血小板凝血时间的作用。
• TRICYCLIC DERIVATIVES AS 5HT 2C? AND 5HT 2B? ANTAGONISTS
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP0757687A1

  公开（公告）日：1997-02-12
• PHENYLALKYLDERIVATE MIT THROMBINHEMMENDER WIRKUNG
  申请人：Boehringer Ingelheim Pharma KG

  公开号：EP0991624A1

  公开（公告）日：2000-04-12